Stifel raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $123 from $94 and keeps a Buy rating on the shares. The firm cites the company’s bivamelagon data in hypothalamic obesity for the target bump. Bivamelagon is now “derisked” on efficacy and “mostly derisked” on safety, the analyst tells investors in a research note. Stifel believes Rhythm now has an opportunity to extend the duration of its melanocortin-4 receptor franchise beyond 2040.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $129 from $91 at Wells Fargo
- Rhythm Pharmaceuticals: Promising Phase 2 Results and Extended Market Exclusivity Boost Price Target
- Rhythm reports bivamelagon achieved statistically significant BMI reductions
- Rhythm Pharmaceuticals initiated with an Outperform at Leerink
- Rhythm Pharmaceuticals Advances Setmelanotide Study in Prader-Willi Syndrome